---
schema_version: "secwatch.filing_event.v1"
accession: "0001962918-24-000104"
form_type: "8-K"
ticker: null
cik: "0001962918"
company_name: "ACELYRIN, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:51:54.936273+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ACELYRIN reports positive Phase 3 izokibep data; pivots to lonigutamab, cuts 1/3 workforce

## Summary
- Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint HiSCR75 (33% vs 21% placebo, p=0.0294); HiSCR90 (25% vs 9%, p=0.0009).
- Company suspends new izokibep investment; focuses on lonigutamab for thyroid eye disease, plans Phase 3 initiation Q1 2025.
- Workforce reduced by ~40 employees (~1/3); expects ~$4.5M severance charges mostly in Q3 2024.
- COO Melanie Gloria steps down effective Oct 31, 2024; receives severance including 12 months salary and equity extension.
- Q2 2024 net loss $85.7M; R&D $76.4M; cash $635.2M projected to fund operations through mid-2027.

## SEC filing metadata
- accession: 0001962918-24-000104
- form_type: 8-K
- cik: 0001962918
- company_name: ACELYRIN, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000104/0001962918-24-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000104/slrn-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001962918-24-000104
- JSON: https://secwatch.observer/filing/0001962918-24-000104.json
- Plain text: https://secwatch.observer/filing/0001962918-24-000104.txt

## Key facts
- Executive change
  Melanie Gloria departed as Chief Operating Officer at ACELYRIN, Inc..
  - Action: stepped down
  - Role: Chief Operating Officer
  source text: On Augus t 9, 2024, the Company and Melanie Gloria mutually agreed that Ms. Gloria will step down from her position as Chief Operating Officer of the Company, effective October 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000104/0001962918-24-000104-index.htm
- Restructurings & Charges
  ACELYRIN, Inc. announced a restructuring with charges of approximately $4.5 million in cash-based expenses related to employee severance payments and benefits affecting enterprise (workforce reduction associated with focus on lonigutamab clinical program) (approximately 40 people, or approximately 1/3 of the Company's existing headcount).
  - Type: restructuring
  - Charge: approximately $4.5 million in cash-based expenses related to employee severance payments and benefits
  - Affected area: enterprise (workforce reduction associated with focus on lonigutamab clinical program)
  - Headcount: approximately 40 people, or approximately 1/3 of the Company's existing headcount
  source text: the Company will focus its efforts primarily on its lonigutamab clinical program in thyroid eye disease and will implement an associated workforce reduction (the “Restructuring Plan”). As part of the Restructuring Plan, the Company’s workforce will be reduced by approximately 40 people, or approximately 1/3 of the Company’s existing headcount. The Company expects to incur charges related to the Restructuring Plan. In this regard, the Company estimates that it will incur approximately $4.5 million in cash-based expenses related to employee severance payments and benefits related to the workforce reduction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1962918/000196291824000104/0001962918-24-000104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.